# PMV Pharmaceuticals, Inc.

**PMVP**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001699382

# None

### No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $116.6M |
| **Warnings** | short runway, thin data<br>not computable: degenerate inputs, fortress balance sheet |
| **Inputs computable** | 6 of 14 |
| **Graded from** | filings received through Mar 6, 2026<br>232 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026 |
| **Last close** | $1.27<br>2026-10-23; market equity $68.2M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 6, 2026*

We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the "guardian of the genome," and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 72.4** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | (2.7%) | (6.6%) | 72.4 | 809 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 47.4** | | | | | |
| Twelve-month failure probability | 0.34% | 0.07% | 79.3 | 247 | 2026-06-30 |
| Altman Z double-prime | (2.34) | (0.33) | 46.6 | 754 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 10.09x | 2.94x | 16.3 | 836 | 2025-12-31 |
| **Growth and financing, sleeve percentile 62.1** | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | |
| *four annual observations are required; found 0* | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *NOPAT must exceed $100,000* | | | | | |
| Asset growth, three years | (24.5%) | 2.1% | 88.2 | 702 | 2025-12-31 |
| Net share issuance, one year | 2.7% | 2.5% | 36.0 | 634 | 2026-03-03 |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 2.1 months |
| Thin data | 6 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-10-23 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (13.6%) | 7.7% | 36 |
| Distance from 52-week high | (29.4%) | (31.4%) | 52 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | (108.4%) | (1.0%) | 6 |
| Book value to price | 1.05 | 0.28 | 86 |
| Sales to price | not computable | 0.30 | |
| Composite equity issuance, five years | 17.7% | 20.5% | 48 |
| Relative strength against the sector, log excess return | (0.36) | (0.14) | 36 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Asset turnover improved | fail |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $12.5M |
| Operating cash flow, four quarters | -$71.3M |
| Months of runway | 2.1 |
| Days since last periodic filing | 71 (10-Q received Aug 14, 2026) |
| Median daily dollar volume, 63 sessions | $519,187 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$77.7M | 2025-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$73.6M | 2025-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 3 | assets | us-gaap:Assets | $116.6M | 2025-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 4 | assets | us-gaap:Assets | $191.3M | 2024-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 5 | current assets | us-gaap:AssetsCurrent | $115.2M | 2025-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $11.4M | 2025-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$446.5M | 2025-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$86.2M | 2025-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 9 | book equity | us-gaap:StockholdersEquity | $104.7M | 2025-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 10 | liabilities | us-gaap:Liabilities | $11.8M | 2025-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 11 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $29,000 | 2025-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 12 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$51.3M | 2024-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 13 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $655,000 | 2024-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 14 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$55.7M | 2023-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 15 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $962,000 | 2023-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 16 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$63.8M | 2022-12-31 | 2025-03-03 | 10-K | 25-030414 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $8.0M | 2022-12-31 | 2025-03-03 | 10-K | 25-030414 |
| 18 | depreciation amortization | us-gaap:Depreciation | $133,000 | 2025-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 19 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$79.9M | 2025-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 20 | income tax | us-gaap:IncomeTaxExpenseBenefit | -$2.2M | 2025-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 21 | current assets | us-gaap:AssetsCurrent | $175.7M | 2024-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 22 | current liabilities | us-gaap:LiabilitiesCurrent | $14.4M | 2024-12-31 | 2026-03-06 | 10-K | 26-095014 |
| 23 | assets | us-gaap:Assets | $252.2M | 2023-12-31 | 2025-03-03 | 10-K | 25-030414 |
| 24 | assets | us-gaap:Assets | $270.3M | 2022-12-31 | 2024-02-29 | 10-K | 24-023062 |
| 25 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 53,329,392 | 2026-03-03 | 2026-03-06 | 10-K | 26-095014 |
| 26 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 51,933,604 | 2025-03-03 | 2025-03-03 | 10-K | 25-030414 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.